Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Proteasome inhibitors for the treatment of multiple myeloma.

Scalzulli E, Grammatico S, Vozella F, Petrucci MT.

Expert Opin Pharmacother. 2018 Mar;19(4):375-386. doi: 10.1080/14656566.2018.1441287. Epub 2018 Feb 26. Review.

PMID:
29478351
2.

[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].

Komada F.

Yakugaku Zasshi. 2018;138(2):229-235. doi: 10.1248/yakushi.17-00194. Japanese.

3.

Inhibition of PAR2 and TRPA1 signals alleviates neuropathic pain evoked by chemotherapeutic bortezomib.

Wang Q, Wang J, Gao D, Li J.

J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):977-983.

PMID:
29254302
4.

Bortezomib-induced syndrome of inappropriate antidiuresis in a patient with multiple myeloma: A case report and literature review
.

Peng B, Chen H, Lou X.

Int J Clin Pharmacol Ther. 2017 Dec;55(12):910-914. doi: 10.5414/CP203109. Review.

PMID:
29092733
5.

Bortezomib-Induced Muscle Toxicity in Multiple Myeloma.

Guglielmi V, Nowis D, Tinelli M, Malatesta M, Paoli L, Marini M, Manganotti P, Sadowski R, Wilczynski GM, Meneghini V, Tomelleri G, Vattemi G.

J Neuropathol Exp Neurol. 2017 Jul 1;76(7):620-630. doi: 10.1093/jnen/nlx043.

PMID:
28863457
6.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.

J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1.

PMID:
28862883
7.

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ.

Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

PMID:
28847998
8.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P.

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.

PMID:
28843768
9.

Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.

Lakshman A, Modi M, Prakash G, Malhotra P, Khadwal A, Jain S, Kumari S, Varma N, Varma S.

Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):513-519.e1. doi: 10.1016/j.clml.2017.06.035. Epub 2017 Jul 6.

PMID:
28842138
10.

Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.

Ikeda T, Fujii H, Nose M, Kamogawa Y, Shirai T, Shirota Y, Ishii T, Harigae H.

Arthritis Res Ther. 2017 Aug 11;19(1):187. doi: 10.1186/s13075-017-1397-7.

11.

[Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].

Solovyev MV, Mendeleeva LP, Pokrovskaya OS, Nareyko MV, Firsova MV, Galtseva IV, Davydova YO, Kapranov NM, Kuzmina LA, Gemdzhian EG, Savchenko VG.

Ter Arkh. 2017;89(7):25-31. doi: 10.17116/terarkh201789725-31. Russian.

PMID:
28766537
12.

Activation of RAGE/STAT3 pathway by methylglyoxal contributes to spinal central sensitization and persistent pain induced by bortezomib.

Wei JY, Liu CC, Ouyang HD, Ma C, Xie MX, Liu M, Lei WL, Ding HH, Wu SL, Xin WJ.

Exp Neurol. 2017 Oct;296:74-82. doi: 10.1016/j.expneurol.2017.07.010. Epub 2017 Jul 18.

PMID:
28729113
13.

Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis.

Sun CY, Li JY, Chu ZB, Zhang L, Chen L, Hu Y.

Biosci Rep. 2017 Jul 27;37(4). pii: BSR20170304. doi: 10.1042/BSR20170304. Print 2017 Aug 31. Review.

14.

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

Lee SM, Zhang Y, Minasian LM, Unger JM, Hershman DL.

Cancer Invest. 2017 Aug 9;35(7):484-489. doi: 10.1080/07357907.2017.1340479. Epub 2017 Jul 10.

PMID:
28692317
15.

Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord.

Xie JD, Chen SR, Chen H, Pan HL.

Neuropharmacology. 2017 Sep 1;123:477-487. doi: 10.1016/j.neuropharm.2017.06.027. Epub 2017 Jun 27.

PMID:
28663117
16.

Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.

Denman J, Manavi K, Cook M.

Int J STD AIDS. 2017 Sep;28(10):1045-1047. doi: 10.1177/0956462417694561. Epub 2017 Feb 17.

PMID:
28632471
17.

Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.

Kumar SK, Laubach JP, Giove TJ, Quick M, Neuwirth R, Yung G, Rajkumar SV, Richardson PG.

Br J Haematol. 2017 Sep;178(5):756-763. doi: 10.1111/bjh.14754. Epub 2017 Jun 7.

PMID:
28591409
18.

Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).

Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, Pönisch W.

J Cancer Res Clin Oncol. 2017 Oct;143(10):2049-2058. doi: 10.1007/s00432-017-2439-x. Epub 2017 May 22.

PMID:
28534173
19.

Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis.

Yuan T, Zhang F, Yao QM, Liu YX, Zhu XJ, Wang X.

PLoS One. 2017 May 22;12(5):e0177950. doi: 10.1371/journal.pone.0177950. eCollection 2017.

20.

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG.

Br J Haematol. 2017 Aug;178(4):547-560. doi: 10.1111/bjh.14708. Epub 2017 May 3.

PMID:
28466536

Supplemental Content

Loading ...
Support Center